Overview
DSIP is classified as a sleep peptide peptide. Improved sleep quality, stress reduction.
Modulates sleep-wake cycle. Promotes delta-wave (deep) sleep phases. Interacts with GABA, serotonin, and opioid pathways.
Also known as: Delta Sleep-Inducing Peptide
Category
Sleep Peptide
Half-Life
0.13h
Route
SubQ
FDA Status
Not Approved
How Does DSIP Work?
Modulates sleep-wake cycle. Promotes delta-wave (deep) sleep phases. Interacts with GABA, serotonin, and opioid pathways.
At the molecular level, DSIP operates through pathways characteristic of the Sleep Peptide class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]DSIP delta sleep promotion in chronic insomniacs
Schneider-Helmert & Schoenenberger: DSIP administered IV to chronic insomniacs decreased nocturnal awakenings, reduced sleep latency, and increased total NREM sleep time.
Evidence: moderate[2]DSIP normalizes sleep in elderly insomniacs
DSIP normalizes sleep architecture in middle-aged and elderly chronic insomniacs, with improvements maintained during follow-up week after treatment cessation.
Evidence: moderate[3]Synthetic DSIP improves disturbed human sleep
Schneider-Helmert (Experientia): Longer sleep duration, fewer interruptions, and increased REM sleep documented without daytime sedation or side effects.
Evidence: moderate[4]Repeated DSIP administration and sleep structure normalization
Study demonstrating that repeated DSIP administration produces cumulative buildup effects, progressively normalizing disturbed sleep patterns.
Evidence: moderate[5]Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Therapeutic peptides, including BPC-157 and TB-500, were found to modulate molecular signaling networks influencing tissue regeneration and inflammation resolution in a 2026 review. The research highlighted their mechanistic potential for orthopaedic applications, noting a current lack of clinical trials.
Evidence: emerging[6]Domain-specific information preservation for Alzheimer's disease diagnosis with incomplete multi-modality neuroimages.
A 2025 study demonstrated that a novel domain-specific information preservation framework significantly outperformed existing methods in imputing missing neuroimage data and identifying Alzheimer's disease status. The dual-stage model successfully captured modality-specific details to improve diagnostic accuracy.
Evidence: emerging[7]Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models.
A 2024 preclinical study demonstrated that a DSIP-CBBBP fusion peptide modulated neurotransmitter levels and exhibited greater restorative effects on sleep and neurotransmitter imbalance compared to DSIP alone in an insomnia mouse model.
Evidence: preclinical[8]Sensing the Bactericidal and Bacteriostatic Antimicrobial Mode of Action Using Raman Deuterium Stable Isotope Probing (DSIP) in Escherichia coli.
A 2024 study demonstrated that Raman deuterium stable isotope probing can successfully discriminate between bactericidal and bacteriostatic antibiotic modes of action in Escherichia coli. Researchers found that changes in the C-D band intensity serve as a quantifiable marker for early identification of antimicrobial activity.
Evidence: preclinical[9]Electronic Prediction of Chemical Contaminants in Aroma of Brewed Roasted Coffee and Quantification of Acrylamide Levels.
A 2024 study demonstrated that an electronic nose device successfully predicted chemical contaminants, including acrylamide and 5-hydroxymethylfurfural, in roasted espresso coffee. Researchers found a strong correlation between the device's electronic signals, sensory defects like a burnt smell, and specific contaminant levels.
Evidence: preclinical[10]Practical N-to-C peptide synthesis with minimal protecting groups.
A 2023 study demonstrated a novel N-to-C peptide synthesis strategy utilizing catalytic thioacid formation and oxidative bond formation with minimal protecting groups. Researchers found this method effectively suppressed epimerization and successfully synthesized the nonapeptide DSIP, offering a cleaner alternative to traditional synthesis.
Evidence: preclinical[11]Single-surface Intensive Phototherapy or Double-Surface Intensive Phototherapy in Neonatal Non-Hemolytic Hyperbilirubinemia: A Comparison of Effectiveness and Complications.
A 2021 randomized clinical trial demonstrated that double-surface intensive phototherapy reduced indirect bilirubin levels faster and shortened hospital stays compared to single-surface intensive phototherapy in neonates. The study found no significant increase in complications between the two treatments.
Evidence: very strong[12]Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke.
A 2021 study on rats demonstrated that intranasal administration of Delta Sleep-Inducing Peptide accelerated the recovery of motor functions following an induced focal stroke. The researchers noted that while brain infarction volume decreased, the difference was not statistically significant.
Evidence: preclinical[13]DSIP-Like KND Peptide Reduces Brain Infarction in C57Bl/6 and Reduces Myocardial Infarction in SD Rats When Administered during Reperfusion.
In a 2021 study, researchers found that the DSIP-like KND peptide significantly reduced myocardial infarction area in rats and brain infarction volume in mice when administered during reperfusion. However, administration during occlusion resulted in 100% mortality in the animal models.
Evidence: preclinical[14]Strategies to Connect Low-Income Communities with the Proposed Sewerage Network of the Dhaka Sanitation Improvement Project, Bangladesh: A Qualitative Assessment of the Perspectives of Stakeholders.
A 2020 qualitative study found that connecting low-income communities in Dhaka to a proposed sewerage network requires improved toilet infrastructure, communal septic tanks, and income-based subsidies. Stakeholders also emphasized the need for government cooperation with NGOs to ensure proper construction and maintenance.
Evidence: emerging[15]A review of the newly identified impurity profiles in methamphetamine seizures.
In a 2020 review, researchers found that analyzing newly identified impurity profiles and stable isotope signatures in methamphetamine seizures provides critical forensic intelligence for identifying synthetic routes and trafficking patterns.
Evidence: emerging[16]Transsynaptic interactions between IgSF proteins DIP-α and Dpr10 are required for motor neuron targeting specificity.
A 2019 study demonstrated that transsynaptic interactions between the proteins DIP-α and Dpr10 are essential for specific motor neuron targeting and connectivity. Researchers found that removing either protein in Drosophila models resulted in the loss of specific axonal branches and neuromuscular junctions.
Evidence: preclinical[17]Stereotyped terminal axon branching of leg motor neurons mediated by IgSF proteins DIP-α and Dpr10.
A 2019 study demonstrated that the precise terminal branching of motor neurons in Drosophila is mediated by the interaction between transmembrane proteins DIP-α and Dpr10. This interaction occurs between axon filopodia and developing muscles to establish coordinated neural circuits.
Evidence: preclinical[18]Phosphorylated delta sleep inducing peptide restores spatial memory and p-CREB expression by improving sleep architecture at high altitude.
A 2018 preclinical study demonstrated that phosphorylated delta sleep-inducing peptide (p-DSIP) improved sleep architecture and restored spatial memory in rats exposed to simulated high-altitude hypoxia. The peptide was found to enhance NREM and REM sleep while upregulating hippocampal CREB phosphorylation.
Evidence: preclinical[19]Ozone Therapy Protects Against Rejection in a Lung Transplantation Model: A New Treatment?
Ozone therapy prevented severe chronic rejection and regulated pathogenic gene expression in a rat lung transplantation model, a 2017 study demonstrated. Researchers found that the treatment significantly delayed rejection onset compared to untreated controls.
Evidence: preclinical[20]Expression and Purification of Delta Sleep-Inducing Peptide Fused with Protein Transduction Domain and Human Serum Albumin in Pichia pastoris.
A 2017 study found that a novel Delta Sleep-Inducing Peptide (DSIP) fusion protein reduced sleep latency and prolonged sleep duration in mice. The researchers demonstrated that the peptide increased the hypnotic effects of pentobarbital in a dose-dependent manner.
Evidence: preclinicalSafety Profile
Limited modern data. Most studies from the 1980s-90s. Safety profile incompletely defined.
| Side Effect | Incidence | Severity |
|---|---|---|
| Headache | ~3% of users | mild |
| Morning grogginess (wrong timing) | ~5% of users | mild |
Sourcing DSIP for Research
If you're looking to source DSIP for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
* Research vendor — verify your regional regulations before purchase.
Full Research Profile
DSIP — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.